Shun Xin Wang Lin
Overview
Explore the profile of Shun Xin Wang Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Touzeau C, Krishnan A, Moreau P, Perrot A, Usmani S, Manier S, et al.
Blood
. 2024 Aug;
144(23):2375-2388.
PMID: 39172760
Teclistamab is a B-cell maturation antigen (BCMA)-directed bispecific antibody approved for the treatment of patients with triple-class exposed relapsed/refractory multiple myeloma (R/RMM). In the phase 1/2 MajesTEC-1 study, a cohort...
2.
Willemin M, Wang Lin S, de Zwart L, Wu L, Miao X, Verona R, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Jun;
13(7):1117-1129.
PMID: 38831634
Cytokine release syndrome (CRS) was associated with teclistamab treatment in the phase I/II MajesTEC-1 study. Cytokines, especially interleukin (IL)-6, are known suppressors of cytochrome P450 (CYP) enzymes' activity. A physiologically...
3.
Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R, et al.
Blood
. 2024 Apr;
144(6):615-628.
PMID: 38657201
Teclistamab, an off-the-shelf B-cell maturation antigen (BCMA) × CD3 bispecific antibody that mediates T-cell activation and subsequent lysis of BCMA-expressing myeloma cells, is approved for the treatment of patients with...
4.
Miao X, Wu L, Wang Lin S, Xu Y, Chen Y, Iwaki Y, et al.
Target Oncol
. 2023 Sep;
18(5):667-684.
PMID: 37713090
Background: Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, is approved in patients with relapsed/refractory multiple myeloma (RRMM) who have previously received an immunomodulatory agent, a proteasome inhibitor, and...
5.
Girgis S, Wang Lin S, Pillarisetti K, Verona R, Vieyra D, Casneuf T, et al.
Blood Adv
. 2022 Aug;
7(4):644-648.
PMID: 36006441
No abstract available.
6.
Girgis S, Wang Lin S, Pillarisetti K, Banerjee A, Stephenson T, Ma X, et al.
Target Oncol
. 2022 Aug;
17(5):609.
PMID: 35913648
No abstract available.
7.
Girgis S, Wang Lin S, Pillarisetti K, Banerjee A, Stephenson T, Ma X, et al.
Target Oncol
. 2022 Jun;
17(4):433-439.
PMID: 35749004
Background: Teclistamab (JNJ-64007957), a B-cell maturation antigen × CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies. Objective: A first-in-human, Phase I, dose escalation study...